spacer
home > pmps > Summer 2013
PUBLICATIONS

Pharmaceutical Manufacturing and Packing Sourcer

pmps
Summer 2013

   
Text
PDF
Industry Insight 
Industry Insight

Graham Hughes casts his eye over a selection of articles from this issue of PMPS.
 
view
download pdf
bullet
Manufacturing
Robotic Innovations

Auto Assembly

Alan Spreckley from ABB observes that pharma manufacturers are finally taking the lead from the food and beverage sector – more and more are implementing robotics in their production processes, and discovering a wide range of improvements.
 
view
download pdf

Spotlight

Coming Home

US initiative Save Your Factory, set up by FANUC Robotics, argues that moving manufacturing overseas is not always the best option. It believes that the many advantages offered by robotic and automated solutions may well persuade North American companies back to domestic soil.

 
view
download pdf
bullet
Cool Chain, Cargo & Logistics
Temperature-Assured Packaging

Hot Topic

New design concepts are constantly emerging with a view to improving product and packaging performance and integrity. Liam Holmes from Sonoco Thermosafe considers a recent case study where single-use options were compared to reusable, sustainable solutions in order to achieve greater temperature assurance.
 
view
download pdf
Ambient Temperature Solutions

A New Profile

Richard Wood at DS Smith Plastics Cool Logistics hopes that a universal formula for developing ambient temperature profi les will revolutionise the temperature-controlled packaging industry, and highlights the need to rely on actual data rather than assumption.
 
view
download pdf
bullet
Labelling 
Regional Labelling

A Common Language

As the trend for expansion into the BRIC countries continues, Vince Postill at PRISYM ID asks whether it is possible to fi nd a global approach to local language labelling for clinical trials?
 
view
download pdf
bullet
Formulations, Ingredients and Excipients
Freeze Drying

Lyophilisation: The Truth

Freeze drying is plagued by numerous misconceptions regarding the best way to integrate the process into existing production lines. Katriona Scoffin at Biopharma Technology Ltd walks us through ten of the most common lyophilisation myths.
 
view
download pdf
User-Friendly Dosage Forms

A Taste of Your Own Medicine

Patient compliance has always been a complex issue, especially with certain groups such as children or the elderly. Overcoming bitter-tasting APIs to create user-friendly alternatives to solid tablets is key to solving this problem, says Detlev Haack at Hermes Pharma.
 
view
download pdf
Fast Dissolve Formulations

Quick Thinking

A better understanding of tablet structure could prove instrumental to the production of fast dissolve dose forms, and lyophilisationbased formulations in particular should tackle speed of dispersion and palatability issues, claim Rob Travers and Leon Grother of Catalent Pharma Solutions.
 
view
download pdf
bullet
Drug Delivery

Device Design

Driving Innovation

Drug delivery and medical devices are playing an increasingly intelligent and customisable role in patient therapy management. Peter Wallrabe from Gerresheimer item GmbH investigates the development of a new device from start to finish.

 
view
download pdf
bullet
Validation & Compliance
Falsified Medicines Directive

Code Word

Manufacturers will be encouraged to implement anti-counterfeiting measures before the European Falsified Medicines Directive becomes mandatory in 2017. Harry Thomason of Travtec emphasises that careful consideration of the way coding is printed on packaging will be crucial to maintain accuracy.

 
view
download pdf

GDP Guidelines

Temperature Control

Two experts from Intelsius Alex Roskoss and Stephen Healy – combine their knowledge to provide both scientific and business views on the European Union’s new Good Distribution Practice guidelines, and debate how far these changes will affect supply chains.



 
view
download pdf
bullet
PACKING & PACKAGING
Leak Detection

Break With Tradition

Philip Stevenson at Sepha compares the variety of methods used to detect leaks in blister packaging. He reveals that long-established destructive methods are slowly being replaced as non-destructive options come to the fore.
 
view
download pdf
Secondary Packaging

All Wrapped Up

Primary packaging concerns are always on the radar of pharma companies when improvements are considered. However, Martin Leeming at TrakRap reminds us that secondary packaging is a key area of innovation which has the potential to deliver huge benefi ts.
 
view
download pdf
bullet
the end of the line
The End of the Line

Emerging Safely

Richard Harrop
suggests the best way to go about entering emerging markets with a temperature-controlled product, and highlights the challenges a new competitor might face.
 
view
download pdf
bullet
CLINICAL TRIAL SUPPLIES & LOGISTICS
Clinical Supplies

Keeping it Cool

Emerging markets can provide pharma companies with huge opportunities to cut costs and reach new patients, but Rachel Griffiths at Biotec Services International stresses that these benefits come with many new challenges.
 
view
bullet
MARKETPLACE & BUSINESS
Q&A: BRIC Expansion

Market Research

Growth into BRIC markets is a hot topic in the pharma industry right now. However, Reenita Das at Frost & Sullivan warns that moving production overseas is not as straightforward as it is often made out to be.
 
view
download pdf
   
spacer


Published quarterly in
February, May,
August, and November

News and Press Releases

IMFINZITM (durvalumab) WITH CHEMOTHERAPY DEMONSTRATED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN THE PHASE III CASPIAN TRIAL

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement